Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in MEDICA 2024, the world's largest medical trade fair, taking place in Düsseldorf, Germany from November 11-14, 2024. The event is expected to attract over 120,000 visitors from 70+ countries and 5,300+ exhibitors. Sonoma will showcase its Microcyn technology-based products for wound care, eye care, dermatological conditions, and other applications at booth F12-5 in Hall 15. The company aims to expand its distributor network and forge new partnerships through this global platform.
Sonoma Pharmaceuticals (NASDAQ:SNOA) ha annunciato la sua partecipazione a MEDICA 2024, la fiera internazionale di medicina più grande del mondo, che si svolgerà a Düsseldorf, Germania, dal 11 al 14 novembre 2024. Si prevede che l'evento attirerà oltre 120.000 visitatori da più di 70 paesi e più di 5.300 espositori. Sonoma presenterà i suoi prodotti basati sulla tecnologia Microcyn per la cura delle ferite, la cura degli occhi, le condizioni dermatologiche e altre applicazioni presso lo stand F12-5 nel Padiglione 15. L'azienda mira a espandere la sua rete di distributori e a creare nuove partnership attraverso questa piattaforma globale.
Sonoma Pharmaceuticals (NASDAQ:SNOA) anunció su participación en MEDICA 2024, la feria comercial médica más grande del mundo, que se llevará a cabo en Düsseldorf, Alemania, del 11 al 14 de noviembre de 2024. Se espera que el evento atraiga a más de 120,000 visitantes de más de 70 países y más de 5,300 expositores. Sonoma mostrará sus productos basados en la tecnología Microcyn para el cuidado de heridas, cuidado ocular, condiciones dermatológicas y otras aplicaciones en el stand F12-5 en el Pabellón 15. La empresa tiene como objetivo expandir su red de distribuidores y forjar nuevas alianzas a través de esta plataforma global.
소노마 제약 (NASDAQ:SNOA)는 독일 뒤셀도르프에서 2024년 11월 11일부터 14일까지 열리는 세계 최대의 의료 무역 박람회 MEDICA 2024에 참여한다고 발표했습니다. 이 행사는 70개국 이상에서 120,000명 이상의 방문객과 5,300개 이상의 전시업체를 끌어들일 것으로 예상됩니다. 소노마는 Hall 15의 부스 F12-5에서 상처 치료, 안과 치료, 피부 질환 및 기타 응용 분야를 위한 마이크로신 기술 기반 제품을 선보일 것입니다. 회사는 이 글로벌 플랫폼을 통해 유통망을 확장하고 새로운 파트너십을 맺는 것을 목표로 하고 있습니다.
Sonoma Pharmaceuticals (NASDAQ:SNOA) a annoncé sa participation à MEDICA 2024, la plus grande foire commerciale médicale au monde, qui se tiendra à Düsseldorf, en Allemagne, du 11 au 14 novembre 2024. L'événement devrait attirer plus de 120 000 visiteurs de plus de 70 pays et plus de 5 300 exposants. Sonoma mettra en avant ses produits basés sur la technologie Microcyn pour les soins des blessures, les soins oculaires, les affections dermatologiques et d'autres applications au stand F12-5 dans le Hall 15. L'entreprise vise à étendre son réseau de distributeurs et à forger de nouveaux partenariats grâce à cette plateforme mondiale.
Sonoma Pharmaceuticals (NASDAQ:SNOA) kündigte seine Teilnahme an MEDICA 2024 an, der größten medizinischen Fachmesse der Welt, die vom 11. bis 14. November 2024 in Düsseldorf, Deutschland, stattfinden wird. Es wird erwartet, dass die Veranstaltung über 120.000 Besucher aus mehr als 70 Ländern und über 5.300 Aussteller anziehen wird. Sonoma wird seine auf der Microcyn-Technologie basierenden Produkte für Wundversorgung, Augenpflege, dermatologische Erkrankungen und weitere Anwendungen am Stand F12-5 in Halle 15 präsentieren. Das Unternehmen hat zum Ziel, sein Vertriebsnetz zu erweitern und neue Partnerschaften über diese globale Plattform zu knüpfen.
- Potential expansion of distributor network through participation in world's largest medical trade fair
- Access to over 120,000 potential customers and partners from 70+ countries
- None.
BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2024 in Düsseldorf, Germany November 11-14, 2024.
MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT. The event brings together professionals, fostering valuable networking opportunities with industry peers, potential partners, and customers from around the globe. It serves as a comprehensive platform for growth, learning, and collaboration within the healthcare sector.
Sonoma Pharmaceuticals is aiming to expand its distributor network and is eager to showcase its products and technologies to a global audience, forging valuable connections with potential partners and industry customers. Interested parties are invited to visit Sonoma Pharmaceuticals' booth (F12-5) in Hall 15 to learn about its patented, innovative, safe, and effective products for the treatment of scar management, atopic dermatitis, and acne, as well as wound care and eyelid infection. For more information, please visit https://sonomapharma.com.
"We are excited to present our portfolio of products at MEDICA, an event celebrated for bringing together thousands of attendees and visitors, including key decision-makers from across the globe. This distinguished platform offers a unique opportunity for us to introduce potential new partners to Sonoma's products, which are supported by our innovative Microcyn technology. MEDICA serves as an exceptional venue for fostering significant collaborations that will be essential in shaping the future direction of enhanced healthcare outcomes," stated Amy Trombly, CEO of Sonoma Pharmaceuticals.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn ® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When and where will Sonoma Pharmaceuticals (SNOA) exhibit at MEDICA 2024?
What products will Sonoma Pharmaceuticals (SNOA) showcase at MEDICA 2024?
How many visitors and exhibitors are expected at MEDICA 2024 where SNOA will exhibit?
